Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 3.96 USD -2.94% Market Closed
Market Cap: 324.6m USD
Have any thoughts about
Sutro Biopharma Inc?
Write Note

Wall Street
Price Targets

STRO Price Targets Summary
Sutro Biopharma Inc

Wall Street analysts forecast STRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STRO is 12.24 USD with a low forecast of 5.05 USD and a high forecast of 21 USD.

Lowest
Price Target
5.05 USD
28% Upside
Average
Price Target
12.24 USD
209% Upside
Highest
Price Target
21 USD
430% Upside

STRO Last Price Targets
Sutro Biopharma Inc

The latest public price target was made on Oct 11, 2024 by Tazeen Ahmad from Bank of America Securities , who expects STRO stock to rise by 203% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Tazeen Ahmad
Bank of America Securities
12 USD
Upside 203%
1 month ago
Oct 11, 2024
BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO)
StreetInsider
Andrew Fein
H.C. Wainwright
12 USD
Upside 203%
1 month ago
Oct 11, 2024
H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO)
StreetInsider
Asthika Goonewardene
Truist Financial
15 USD
Upside 279%
2 months ago
Aug 16, 2024
Sutro Biopharma (STRO) PT Lowered to $15 at Truist Securities
StreetInsider
David Nierengarten
Wedbush
8 USD
Upside 102%
6 months ago
May 14, 2024
Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)
StreetInsider
James Shin
Deutsche Bank
10 USD
Upside 153%
6 months ago
May 14, 2024
Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank
StreetInsider
Edward Tenthoff
Piper Sandler
11 USD
Upside 178%
7 months ago
Apr 3, 2024
Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler
StreetInsider
Jay Olson
Oppenheimer
10 USD
Upside 153%
7 months ago
Apr 3, 2024
Oppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO)
StreetInsider
Asthika Goonewardene
Truist Financial
18 USD
Upside 355%
7 months ago
Apr 2, 2024
Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities
StreetInsider
Show More Price Targets
Show Less Price Targets
Tazeen Ahmad
Bank of America Securities
Price Target 12 USD
Upside/Downside 203%
View Source
Andrew Fein
H.C. Wainwright
Price Target 12 USD
Upside/Downside 203%
View Source
Asthika Goonewardene
Truist Financial
Price Target 15 USD
Upside/Downside 279%
View Source
David Nierengarten
Wedbush
Price Target 8 USD
Upside/Downside 102%
View Source
James Shin
Deutsche Bank
Price Target 10 USD
Upside/Downside 153%
View Source
Edward Tenthoff
Piper Sandler
Price Target 11 USD
Upside/Downside 178%
View Source
Jay Olson
Oppenheimer
Price Target 10 USD
Upside/Downside 153%
View Source
Asthika Goonewardene
Truist Financial
Price Target 18 USD
Upside/Downside 355%
View Source
Show More Price Targets
Show Less Price Targets
Sutro Biopharma Inc Competitors:
Price Targets
CMPS
Compass Pathways PLC
683% Upside
BIOPOR
Bioporto A/S
72% Upside
ANIK
Anika Therapeutics Inc
107% Upside
VCEL
Vericel Corp
5% Upside
9688
Zai Lab Ltd
59% Upside
ALEC
Alector Inc
174% Upside
9926
Akeso Inc
6% Upside
ALDX
Aldeyra Therapeutics Inc
138% Upside

Revenue
Forecast

Revenue Estimate
Sutro Biopharma Inc

For the last 6 years the compound annual growth rate for Sutro Biopharma Inc's revenue is 20%. The projected CAGR for the next 3 years is -21%.

20%
Past Growth
-21%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Sutro Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Sutro Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STRO's stock price target?
Price Target
12.24 USD

According to Wall Street analysts, the average 1-year price target for STRO is 12.24 USD with a low forecast of 5.05 USD and a high forecast of 21 USD.

What is Sutro Biopharma Inc's Revenue forecast?
Projected CAGR
-21%

For the last 6 years the compound annual growth rate for Sutro Biopharma Inc's revenue is 20%. The projected CAGR for the next 3 years is -21%.

Back to Top